Literature DB >> 8616755

Results of extensive surgery for pancreatic carcinoma.

T Nagakawa1, M Nagamori, F Futakami, Y Tsukioka, M Kayahara, T Ohta, K Ueno, I Miyazaki.   

Abstract

BACKGROUND: Since 1973, 210 patients with pancreatic carcinoma have undergone surgery in our clinic, including 144 with carcinoma of the head of the pancreas. Of these 144 patients, macroscopic curative resections were performed on 53 (36.8%). Five patients (9.4%) died within 30 postoperative days, and an additional 3 (5.7%) died within 60 days. The overall median survival was 13 months. Eight of the patients who underwent macroscopic curative resection survived 5 years, giving a 5-year survival rate of 27.4% using the Kaplan-Meier method. The 5-year survival rate was 39.7% after a microscopically curative resection and 0% after a microscopically noncurative resection.
METHODS: Outcome was compared based on the extent of pancreatic cancer by constructing survival curves according to the general rules published by the Japan Pancreas Society.
RESULTS: There was no statistically significant difference in survival based on tumor size or stage. However, there was a significant difference in the survival of patients with the absence (so) or presence (se) of invasion to the anterior capsule of the pancreas, the absence (rpo) or presence (rpe) of invasion of the retroperitoneal tissue, the absence (ew0) or presence (ew2) of invasion at the surgical margin of resection, and the extent (n0 to n2) of lymph node metastasis.
CONCLUSIONS: The results of this study suggest that extended radical pancreatectomy may be indicated for patients with pancreatic carcinoma because standard dissection may fail when the tumor has spread to the retroperitoneum or extrapancreatic nerve plexus.

Entities:  

Mesh:

Year:  1996        PMID: 8616755

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  47 in total

Review 1.  Adjuvant therapy in pancreatic cancer.

Authors:  P Ghaneh; J Slavin; R Sutton; M Hartley; J P Neoptolemos
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 2.  Recent advances in the surgical treatment of pancreatic cancer.

Authors:  A Shankar; R C Russell
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

3.  Can intestinal innervation be preserved in pancreatoduodenectomy for cancer? Results of an anatomical study.

Authors:  M Nano; H Dal Corso; M Ferronato; M Solej; J P Hornung
Journal:  Surg Radiol Anat       Date:  2003-02-25       Impact factor: 1.246

4.  Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings.

Authors:  Shoichi Hishinuma; Yoshiro Ogata; Moriaki Tomikawa; Iwao Ozawa; Kaoru Hirabayashi; Seiji Igarashi
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

5.  Extended resection for pancreatic adenocarcinoma.

Authors:  T M van Gulik; A Nakao; H Obertop
Journal:  HPB (Oxford)       Date:  2002       Impact factor: 3.647

6.  Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry.

Authors:  M Carpelan-Holmström; S Nordling; E Pukkala; R Sankila; J Lüttges; G Klöppel; C Haglund
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

7.  Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial.

Authors:  Ryuichiro Doi; Masayuki Imamura; Ryo Hosotani; Toshihide Imaizumi; Takashi Hatori; Ken Takasaki; Akihiro Funakoshi; Hideyuki Wakasugi; Takehide Asano; Shoichi Hishinuma; Yoshiro Ogata; Makoto Sunamura; Koji Yamaguchi; Masao Tanaka; Sonshin Takao; Takashi Aikou; Koichi Hirata; Hiroyuki Maguchi; Koichi Aiura; Tatsuya Aoki; Akira Kakita; Makoto Sasaki; Masahiko Ozaki; Satoru Matsusue; Shunichi Higashide; Hideki Noda; Seiyo Ikeda; Shunzo Maetani; Shigeaki Yoshida
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

8.  Clinical and pathologic prognostic factors for curative resection for pancreatic cancer.

Authors:  M V Perini; A L Montagnini; J Jukemura; S Penteado; E E Abdo; R Patzina; I Cecconello; J E M Cunha
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

9.  Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma.

Authors:  E J Clark; S Connor; M A Taylor; K K Madhavan; O J Garden; R W Parks
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

10.  A patient with unresectable advanced pancreatic cancer achieving long-term survival with gemcitabine chemotherapy.

Authors:  Yoshiki Okamoto; Takashi Maeba; Keitarou Kakinoki; Keiichi Okano; Kunihiko Izuishi; Hisao Wakabayashi; Hisashi Usuki; Yasuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.